Markets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
Widgets
More
Search stocks
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Overview
Buy Sell Zone
F&O
Financials
News
All
News
Earnings Calls
Corporate Announcements
Research Reports
Reports
Technicals
Technicals
Share Price History
Delivery
Shareholding
Shareholding
Monthly MF Holdings
Bulk Block Deals
Insider Trading & SAST
Deals
Bulk Block Deals
Insider Trading & SAST
Corporate Actions
All
Dividend
Bonus
Split
Rights
Board Meetings
Alerts
(1)
About
Lupin Ltd.
NSE: LUPIN
|
BSE: 500257
|
ISIN: INE326A01037
|
Industry: Pharmaceuticals
US FDA Approval
|
Mid-range Performer
1919.8000
-43.70
(
-2.23
%)
NSE
Sep 26, 2025
15:31 PM
Volume:
1.1M
Share on Facebook
Tweet
Share on LinkedIn
Share via Whatsapp
Lupin Ltd.
29 May 2017
US FDA Approval
1919.80
-2.23%
Lupin Ltd Q4FY17 results comment
Results Update:
Lupin Ltd.
by
HDFC Securities
HDFC Securities
Revenue fell by 5.52% to Rs. 4161.88 Cr in Q4FY17 when compared to the previous quarter.
Lupin Ltd. is trading below all available SMAs
More from Lupin Ltd.
Recommended
The new H1B fee: Who will it hurt the most?
The Baseline |
26 Sep 2025, 05:06PM
Five Interesting Stocks Today - September 26, 2025
The Baseline |
26 Sep 2025, 04:56PM
Lupin expects normalization by September quarter
|
17 Apr 2020